Avenue Therapeutics, Inc.

$0.26 USD

$0 (0.0%)

Volume: 54
Average Volume: 2.79K
Market Capitalization: $856.69K
P/E Ratio: -0.47
Dividend Yield: 0.00%
Price Target: $12.00

Year High: $0.97
Year Low: $0.15
Day High: —
Day Low: —
Payout Ratio: $0.00
Current Ratio: $1.90

Industry, Sector & symbol

Stock Exchange	OTC
CEO	Alexandra MacLean
Industry	Biotechnology
Sector	Healthcare
Current Symbol	ATXI
CUSIP	05360L403
CIK	0001644963
Web	https://www.avenuetx.com
Phone	781 652 4500
Currency	USD
Employees	1
Country	US

Liquidity

Debt-to-Equity Ratio	0.00
Payout Ratio	0.00
Current Ratio	1.90
Quick Ratio	1.90
Cash Ratio	1.90

Sales & Book Value

Annual Sales	$1.4M
Price / Sales	0.59
Cash Flow	-0.33
Price / Cash Flow	-0.76
Price / Book	0.69

Price Target and Rating

Average Stock Price Forecast	$12.00
High Stock Price Forecast	$12.00
Low Stock Price Forecast	$12.00
Forecast Upside/Downside	-97.83%
Consensus Rating	Sell
Rating Score(0-5)	2
Research Coverage	1 Analysts

Profitability

EPS (Most Recent Fiscal Year)	-$0.93
Trailing P/E Ratio	-0.47
PEG Ratio	0.00
P/E Growth	0.00
Net Income	-$2.91M
Net Margin	-124.79%
Pretax Margin	-127.07%
Return on Equity	-65.83%
Return on Assets	-70.99%

Financials Score

AltmanZ Score	-61.47
Piotroski Score	2.00
Working Capital	1.15M
Total Assets	2.47M
Ebit	-2.06M
Market Cap	823.74K
Total Liabilities	1.27M

Poll Results

About Avenue Therapeutics, Inc. (OTC:ATXI) Stock

Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York. ...

Comparing Avenue Therapeutics (NASDAQ:ATXI) & Graybug Vision (NASDAQ:GRAY)

2026-04-25 02:30:52

Insider and Institutional Ownership 17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 49.9% of Graybug Vision shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by company insiders. Comparatively, 7.9% of Graybug Vision shares are held by company insiders. Strong institutional ownership is an indication that large money

Frequently Asked Questions

What is the current Avenue Therapeutics, Inc. (ATXI) stock price?: Avenue Therapeutics, Inc.(OTC:ATXI) stock price is $0.26 in the last trading session. During the trading session, ATXI stock reached the peak price of $0.9699 while $0.15 was the lowest point it dropped to. The percentage change in ATXI stock occurred in the recent session was 0.0% while the dollar amount for the price change in ATXI stock was $0.
ATXI's industry and sector of operation?: The OTC listed ATXI is part of Biotechnology industry that operates in the broader Healthcare sector.
Who are the executives of ATXI?: Alexandra MacLean | Chief Executive Officer & Director
Lindsay Allan Rosenwald | Executive Director
David Jin | Interim Chief Financial Officer, Chief Operating Officer & Corporate Secretary
|
|
How many employees does ATXI have?: Number of ATXI employees currently stands at 1. ATXI operates from 1140 Avenue of the America, New York City, NY 10036, US.

Link for ATXI official website?: Official Website of ATXI is: https://www.avenuetx.com
How do I contact ATXI?: ATXI could be contacted at phone #781 652 4500 and can also be accessed through its website. ATXI operates from 1140 Avenue of the America, New York City, NY 10036, US.
How many shares of ATXI are traded daily?: The average number of ATXI shares traded daily for last 3 months was 2.79K.
What is the market cap of ATXI currently?: The market value of ATXI currently stands at $856.69K with its latest stock price at $0.26